Datamonitor Healthcare Strategy: Immuno-Oncology Deal Trends, 2014–18
August 05, 2019
Cancer research and treatment has evolved considerably over recent years, and one of the most promising modalities to emerge is
immuno-oncology.
Arguably one of the greatest breakthroughs in modern medicine, immuno-oncology essentially unlocks the breaks on the body's
natural ability to attack and fight off cancer.
Immuno-oncology therapeutics help to reprogram the immune system so that it recognizes and destroys cancer cells, which under
normal circumstances may be able to evade an immune system attack.
Pharmaceutical companies are pursuing several types of immuno-oncology products, including checkpoint inhibitors, tumor necrosis
factor receptor agonists, adoptive T-cell therapies such as chimeric antigen receptor T-cell (CAR-T) technology, tumor-infiltrating
lymphocytes, and vaccines.
As of July 2019, there are 25 immuno-oncology therapies (including monotherapies and combinations with chemotherapies or other
products, but excluding biosimilars) launched throughout the world for a wide range of solid and hematological tumors.
This Datamonitor Healthcare report contains a Strategy module.
| Disease Group Covered: |
Oncology
|
